Abstract P031: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with de-differentiated liposarcoma

Mapping Intimacies ◽

10.1158/1535-7163.targ-21-p031 ◽

2021 ◽

Author(s):

Mrinal Gounder ◽

Gary Schwartz ◽

Robin Jones ◽

Shreyaskumar Patel ◽

Silvia Stacchiotti ◽

...

Keyword(s):

Phase 3 ◽

Multicenter Phase ◽

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance

Radiotherapy and Oncology ◽

10.1016/j.radonc.2016.06.019 ◽

2016 ◽

Vol 120 (1) ◽

pp. 119-123 ◽

Author(s):

Oliver J. Ott ◽

Vratislav Strnad ◽

Guido Hildebrandt ◽

Daniela Kauer-Dorner ◽

Hellen Knauerhase ◽

...

Keyword(s):

Patient Compliance ◽

Accelerated Partial Breast Irradiation ◽

Partial Breast Irradiation ◽

External Beam ◽

Whole Breast Irradiation ◽

Breast Irradiation ◽

Phase 3 ◽

Multicenter Phase ◽

Download Full-text

P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)02264-3 ◽

2021 ◽

Vol 21 ◽

pp. S109-S110

Author(s):

Irene Ghobrial ◽

Paula Rodríguez-Otero ◽

Youngil Koh ◽

Joaquín Martínez-López ◽

Gurdeep Parmar ◽

...

Keyword(s):

Multiple Myeloma ◽

High Risk ◽

Phase 3 ◽

Preliminary Results ◽

Multicenter Phase ◽

Smoldering Multiple Myeloma

Download Full-text

321 A RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO AND NAPROXEN CONTROLLED, MULTICENTER PHASE 3 STUDY OF NAPROXCINOD IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE: EFFICACY RESULTS FOLLOWING 13-WEEK TREATMENT

Osteoarthritis and Cartilage ◽

10.1016/s1063-4584(09)60343-5 ◽

2009 ◽

Vol 17 ◽

pp. S171-S172

Author(s):

C.E. Marrero ◽

C. Tuten ◽

T. Shamim ◽

V. Awasty ◽

J. Agaiby ◽

...

Keyword(s):

Osteoarthritis Of The Knee ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Download Full-text

LBP-008: SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis pati

Journal of Viral Hepatitis ◽

10.1111/jvh.13_12935 ◽

2018 ◽

Vol 25 ◽

pp. 198-199

Keyword(s):

Clinical Trial ◽

Hepatitis C ◽

Phase 3 ◽

Multicenter Phase

Download Full-text

Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial

The American Journal of Gastroenterology ◽

10.14309/00000434-201210001-01522 ◽

2012 ◽

Vol 107 ◽

pp. S609-S610 ◽

Author(s):

Brian Feagan ◽

Paul Rutgeerts ◽

Bruce Sands ◽

William Sandborn ◽

Jean-Frederic Colombel ◽

...

Keyword(s):

Ulcerative Colitis ◽

Maintenance Therapy ◽

Phase 3 ◽

Double Blind ◽

Multicenter Phase

Download Full-text

PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

Annals of Oncology ◽

10.1093/annonc/mdw200.08 ◽

2016 ◽

Vol 27 ◽

pp. ii104

Author(s):

J. Kisro ◽

A. Cohn ◽

T. Yoshino ◽

E. Van Cutsem ◽

S. Hegewisch-Becker ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Resource Utilization ◽

Second Line ◽

Metastatic Colorectal Carcinoma ◽

Phase 3 ◽

Double Blind ◽

Multicenter Phase ◽

Utilization Data

Download Full-text

Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2019.12.648 ◽

2020 ◽

Vol 145 (2) ◽

pp. AB71

Author(s):

John Sleasman ◽

William Lumry ◽

Iftikhar Hussain ◽

H. James Wedner ◽

James Harris ◽

...

Keyword(s):

Immune Globulin ◽

Phase 3 ◽

Humoral Immunodeficiency ◽

Multicenter Phase

Download Full-text

Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study

The Journal of Urology ◽

10.1016/j.juro.2007.08.137 ◽

2008 ◽

Vol 179 (1) ◽

pp. 152-155 ◽

Author(s):

M.R. Smith ◽

S.B. Malkowicz ◽

F. Chu ◽

J. Forrest ◽

D. Price ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Mineral Density ◽

Clinical Study ◽

Androgen Deprivation Therapy ◽

Bone Mineral ◽

Interim Analysis ◽

Androgen Deprivation ◽

Mineral Density ◽

Phase 3 ◽

Multicenter Phase

Download Full-text

Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

10.1158/1538-7445.sabcs14-s5-07 ◽

2015 ◽

Author(s):

Brian Leyland-Jones ◽

Igor Bondarenko ◽

Gia Nemsadze ◽

Vitaliy Smirnov ◽

Iryna Litvin ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Supportive Care ◽

Metastatic Breast ◽

Epoetin Alfa ◽

Standard Chemotherapy ◽

Phase 3 ◽

Multicenter Phase

Download Full-text